Grounded in Experience, Focused on Outcomes
Built on clarity, collaboration, and a deep understanding of EU regulatory decision-making, Aurora Insights offers tailored support across key milestones—from orphan designation and paediatric development to scientific advice and PRIME eligibility. Investors also rely on the consultancy for impartial evaluations of strategy, timelines, and risk—strengthening due diligence and asset positioning.
Founded by Dr. Adriana Andrić, a former EU regulator with over 15 years of experience in European medicines regulation, Aurora Insights draws on a career shaped by senior roles at the HALMED and committee mandates at the EMA, including the SAWP, PDCO, and COMP.Dr. Andrić has supported a broad range of regulatory procedures across diverse therapeutic areas and product types, including well over 100 scientific advice procedures and dozens of paediatric plans and orphan drug designations. This experience translates into practical, actionable guidance aligned with scientific goals, agency expectations, and commercial timelines.
Whether you’re refining a regulatory strategy, preparing a high-stakes submission, or evaluating regulatory risk — if you’re looking for expert support to navigate the complex EU regulatory landscape, you’re in the right place: where vision meets regulatory excellence.